CASTLEVAX, Inc.
CastleVax is a clinical-stage vaccine platform company dedicated to developing innovative vaccines using a proprietary Newcastle Disease Virus (NDV) platform. Their mission is to create safe, effective, and accessible vaccines for all humans, everywhere, with a focus on pandemic preparedness and addressing unmet medical needs. They leverage advanced vaccine technology, including mucosal delivery, to combat respiratory diseases like COVID-19 and other emerging viruses.
Industries
Nr. of Employees
small (1-50)
Products
Next-generation intranasal NDV-vectored COVID-19 booster vaccine (intranasal)
A live NDV-vectored intranasal booster candidate expressing a multi-proline prefusion-stabilized SARS-CoV-2 spike protein designed to induce mucosal IgA and systemic neutralizing antibodies; progressed through early clinical evaluation and being advanced into larger efficacy testing.
Systemically delivered NDV-vectored COVID-19 vaccine (inactivated/intramuscular)
An NDV-vectored vaccine formulated for intramuscular administration (inactivated option available) intended to provide a systemically delivered alternative to intranasal formulations; evaluated in multiple Phase 1–3 programs by manufacturing partners.
Pipeline mucosal vaccine candidates (RSV+HMPV bivalent; Norovirus mucosal)
Preclinical/early-development NDV-vectored programs for additional respiratory and enteric pathogens including a bivalent mucosal RSV+HMPV candidate and a mucosal Norovirus candidate, built on the same NDV vector engineering approach.
Next-generation intranasal NDV-vectored COVID-19 booster vaccine (intranasal)
A live NDV-vectored intranasal booster candidate expressing a multi-proline prefusion-stabilized SARS-CoV-2 spike protein designed to induce mucosal IgA and systemic neutralizing antibodies; progressed through early clinical evaluation and being advanced into larger efficacy testing.
Systemically delivered NDV-vectored COVID-19 vaccine (inactivated/intramuscular)
An NDV-vectored vaccine formulated for intramuscular administration (inactivated option available) intended to provide a systemically delivered alternative to intranasal formulations; evaluated in multiple Phase 1–3 programs by manufacturing partners.
Pipeline mucosal vaccine candidates (RSV+HMPV bivalent; Norovirus mucosal)
Preclinical/early-development NDV-vectored programs for additional respiratory and enteric pathogens including a bivalent mucosal RSV+HMPV candidate and a mucosal Norovirus candidate, built on the same NDV vector engineering approach.
Services
License of NDV-vectored vaccine platform and transfer of manufacturing know-how to independent manufacturers, including support for process adoption in low- and middle-income country sites.
Design and operational execution of vaccine clinical trials including early-phase immunogenicity studies and planning of large randomized efficacy trials.
Support for CMC development, facility authorization processes, process scale-up, and quality systems to enable industrial production of vaccine candidates.
License of NDV-vectored vaccine platform and transfer of manufacturing know-how to independent manufacturers, including support for process adoption in low- and middle-income country sites.
Design and operational execution of vaccine clinical trials including early-phase immunogenicity studies and planning of large randomized efficacy trials.
Support for CMC development, facility authorization processes, process scale-up, and quality systems to enable industrial production of vaccine candidates.
Expertise Areas
- Mucosal vaccine development
- Viral vector engineering (NDV)
- Antigen design and prefusion stabilization
- Egg-based vaccine manufacturing and tech transfer
Key Technologies
- NDV-vectored vaccines
- Intranasal (mucosal) vaccine delivery
- Live-attenuated and inactivated vaccine formulations
- Egg-based (embryonated chicken egg) manufacturing
News & Updates
CastleVax Inc. received a $338 million award from BARDA to develop an intranasal NDV-based COVID-19 booster vaccine into Phase 2b clinical efficacy testing.
Interim results show that intranasal delivery of the vaccine induces a robust mucosal immune response, potentially preventing infection and transmission.
The Patria® vaccine, licensed from CastleVax, demonstrated effectiveness as a COVID-19 booster with a good safety profile.
The Thai GPO's NDV-HXP-S vaccine candidate has entered phase 3 clinical evaluation as a booster dose, with ongoing trials in Thailand.
Clinical trials in Mexico and Thailand show that Patria is safe and induces a strong immune response.
The NDV-HXP-S vaccine, developed at Mount Sinai, shows promise for local production in low- and middle-income countries and induces a strong immune response.
CastleVax Inc. received a $338 million award from BARDA to develop an intranasal NDV-based COVID-19 booster vaccine into Phase 2b clinical efficacy testing.
Interim results show that intranasal delivery of the vaccine induces a robust mucosal immune response, potentially preventing infection and transmission.
The Patria® vaccine, licensed from CastleVax, demonstrated effectiveness as a COVID-19 booster with a good safety profile.
The Thai GPO's NDV-HXP-S vaccine candidate has entered phase 3 clinical evaluation as a booster dose, with ongoing trials in Thailand.
Clinical trials in Mexico and Thailand show that Patria is safe and induces a strong immune response.
The NDV-HXP-S vaccine, developed at Mount Sinai, shows promise for local production in low- and middle-income countries and induces a strong immune response.